Paper Details

  1. Home
  2. Paper Details

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

Author: DervenisChristos, FountzilasGeorge, GoudopoulouAthina, Kalogera-FountzilaAnna, KalogerasKonstantine T, KaravasilisVasilios, KoliouGeorgia-Angeliki, LinardouHelena, PapadopoulosGeorgios, PapatsibasGeorge, PectasidesDimitrios, PentheroudakisGeorge, RallisGrigorios, SamantasEpaminontas, SgourosJoseph, SkondraMaria, VarthalitisIoannis

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of gemcitabine (G) and temsirolimus (T) was feasible in patients with locally advanced or metastatic pancreatic carcinoma (MPC) with manageable side effects. However, the combination lacked clinical efficacy, with a median progression-free survival of 2.69 months and a 6-month progression-free survival rate of 30.9%.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES: Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11523-018-0605-y

データ提供：米国国立医学図書館（NLM）

Gemcitabine and Temsirolimus for Pancreatic Cancer

Pancreatic cancer, a formidable foe, is known for its aggressive nature and dismal prognosis. The quest for effective treatments continues. This study, led by the Hellenic Cooperative Oncology Group, investigates the effectiveness of a novel drug combination, gemcitabine and temsirolimus, for patients with advanced pancreatic cancer. They aimed to determine the maximum tolerated dose and side effects (Phase I) and then assess the effectiveness of the combination in terms of progression-free survival (Phase II). The study concluded that while the combination is feasible with manageable side effects, it lacks clinical efficacy. This research provides valuable insights into the challenges of treating pancreatic cancer and underscores the ongoing need for innovative therapies.

The Reality of Pancreatic Cancer Treatment

Despite the diligent efforts of researchers and clinicians, pancreatic cancer remains a difficult disease to treat. This study, despite showing a feasible combination of gemcitabine and temsirolimus, reveals a lack of clinical efficacy. It highlights the need for continued research to find new, effective therapies for patients battling this challenging disease.

Hope for the Future

While this study may not have yielded the desired breakthrough, it serves as a building block in the ongoing quest for better treatments for pancreatic cancer. Like a patient camel traversing a vast desert, researchers persevere in their pursuit of knowledge, driven by the hope of finding a solution to this debilitating disease.

Dr.Camel's Conclusion

This study sheds light on the complexities of cancer research, particularly the ongoing search for effective treatments for pancreatic cancer. While the combination of gemcitabine and temsirolimus showed promise in terms of tolerability, it ultimately fell short of delivering the desired clinical efficacy. However, the journey towards finding a cure for pancreatic cancer continues, and each study, even those with less-than-ideal outcomes, contributes to the larger body of knowledge that will eventually lead to breakthroughs.
Date :
  1. Date Completed 2019-09-17
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

30488350

DOI: Digital Object Identifier

10.1007/s11523-018-0605-y

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.